Phase 1 dose-escalation study of a novel oral PI3K/mTOR dual inhibitor, LY3023414, in patients with cancer

LY3023414 is an oral, selective adenosine triphosphate-competitive inhibitor of class I phosphatidylinositol 3-kinase isoforms, mammalian target of rapamycin, and DNA-protein kinase in clinical development. We report results of a 3 + 3 dose-escalation Phase 1 study for twice-daily (BID) dosing of LY...

Descripción completa

Detalles Bibliográficos
Autores principales: Kondo, Shunsuke, Tajimi, Masaomi, Funai, Tomohiko, Inoue, Koichi, Asou, Hiroya, Ranka, Vinay Kumar, Wacheck, Volker, Doi, Toshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575488/
https://www.ncbi.nlm.nih.gov/pubmed/32578154
http://dx.doi.org/10.1007/s10637-020-00968-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575488/
https://www.ncbi.nlm.nih.gov/pubmed/32578154
http://dx.doi.org/10.1007/s10637-020-00968-5

Ejemplares similares